Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Debiopharm’s Appeal on Elplat Patent Suit Rejected: Nippon Chemiphar/Nagase
July 13, 2017
- Daiichi Sankyo Links Up with Max Planck Innovation, LDC on Cancer Research
July 13, 2017
- Vemlidy Counterfeit with Japanese Label Found in China
July 13, 2017
- Biogen, Univ. of Tokyo Establish Research Program on “Pharmacotherapeutics for Neuropsychiatric Disorders”
July 13, 2017
- Astellas Pursuing Corrective Measures after ABPI Suspension Extension: CEO
July 12, 2017
- Astellas Eager to Take in External Resources; Key Xtandi Data Out Later This Year
July 12, 2017
- Boehringer Ingelheim, NCC Forge Comprehensive Partnership
July 12, 2017
- Daiichi Sankyo’s Oncolytic Virus Gets Orphan Status
July 12, 2017
- Ethical Drug Sales Tick Up 1.7% in May: Crecon
July 12, 2017
- Mundipharma Inks Partnership with J1 Soccer Team, Isodine Logo Put on Uniform
July 11, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
- Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
- Boxed Warning Erased for Pfizer Smoking Cessation Aid Champix
July 10, 2017
- MSD, Bayer Yakuhin to Comarket Zetia-Statin Combo Drugs
July 10, 2017
- Maruho Takes Over Marketing Authorization for Astellas’ Protopic Ointment
July 10, 2017
- RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
- Konica Minolta Buying US Diagnostics Firm to Fully Enter Precision Medicine Biz
July 7, 2017
- Nippon Chemiphar Sounds Positive about Authorized Generic Biz
July 7, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…